In this edition:
SCNSL: prognostic factors & outcomes
TRIANGLE: ibrutinib-containing treatment ± ASCT for younger MCL
inMIND: tafasitamab + lenalidomide & rituximab for relapsed/refractory FL
Real-world outcomes with epcoritamab & glofitamab for relapsed/refractory large B-cell lymphoma
RAPID: 16-year survival data
CALGB50604 vs. ACCRULY1601: novel agents in early-stage HL
GAINED: outcomes of primary mediastinal B-cell lymphoma
ZUMA-5: 5-year follow-up
Outcomes after ASCT & allo-SCT for T-cell entities
POLARIX: 5-year follow-up
Please login below to download this issue (PDF)